EC Number   |
Application |
Reference |
|---|
   3.4.22.60 | medicine |
Actinobacillus actinomycetemcomitans cytolethal distending toxin acts as an immunosuppressive factor, it possesses the ability to induce human T-cell apoptosis through activation of caspase-7 |
668912 |
| 3.4.22.60 | medicine |
acute hemorrhagic conjunctivitis, Enterovirus 70 infection induces caspase-7-mediated apoptosis |
670996 |
| 3.4.22.60 | medicine |
caspase-7 may play a role in ataxin-7 proteolysis and pathology of spinocerebellar ataxia type 7. Inhibition of this protease may be therapeutically important |
680829 |
| 3.4.22.60 | medicine |
cleavage of claspin by caspase-7 inactivates the Chk1 signaling pathway, this mechanism may regulate the balance between cell cycle arrest and induction of apoptosis during response of genotoxic stress |
669391 |
| 3.4.22.60 | medicine |
hydrophobic P5 residue has a favorable contribution to the recognition and hydrolysis of substrates but not by caspase-7, this information helps to design specific inhibitors for each caspase |
669888 |
| 3.4.22.60 | medicine |
involvement of the CASP7 gene in the susceptibility to rheumatoid arthritis. The higher production of the no functional variant of CASP7 by individuals with a particular genotype could be the basis of this association |
682831 |
| 3.4.22.60 | medicine |
low-dosage topoisomerase II inhibitor etoposide effectively inhibits proliferation rate |
667232 |
| 3.4.22.60 | medicine |
strong correlation between caspase-7 activity, normal brain development, and apoptotic DNA fragmenation in Casp3-/-mice |
669946 |
| 3.4.22.60 | medicine |
strong correlation between caspase-7 activity, normal brain development, and apoptotic DNA fragmenation in Casp3-/-mice, caspase-7 is a caspase-3 surrogate in Casp3-/-mice |
669946 |
| 3.4.22.60 | medicine |
substitution in the P1' position could be used in synergy with other elements to obtain highly potent and isozyme-selective caspase inhibitors |
670461 |
